Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/2/2025

Management of Diarrhea-Predominant IBS

First-Line Treatment Approach

  • The American Gastroenterological Association recommends starting with loperamide 2-4 mg up to four times daily as first-line pharmacologic therapy for diarrhea control, combined with standard dietary advice including regular meals, adequate hydration, and limiting caffeine, alcohol, and gas-producing foods 1, 2, 3
  • Patients should maintain regular meal patterns without skipping meals or leaving long intervals between eating, and drink at least 8 glasses of fluid daily, prioritizing water and non-caffeinated beverages 2
  • Limiting tea and coffee to 3 cups daily and reducing alcohol and carbonated beverages is also recommended 2
  • Restricting fresh fruit to 3 portions daily and avoiding insoluble fiber entirely, such as wheat bran, as it consistently worsens symptoms, particularly bloating, is advised 2, 3
  • Consider soluble fiber, such as ispaghula/psyllium, starting at 3-4 g/day, increasing gradually, though this is more beneficial for constipation-predominant IBS 2, 3
  • Loperamide 2-4 mg up to four times daily is the most effective first-line agent for reducing stool frequency, urgency, and fecal soiling, and should be titrated carefully to avoid constipation, abdominal pain, bloating, and nausea 1, 3, 4
  • Codeine 30-60 mg 1-3 times daily is an alternative but causes more CNS side effects and dependency risk 1, 4
  • Antispasmodics with anticholinergic properties, such as dicyclomine and hyoscine, can be added for pain relief, and patients should be warned about common side effects: dry mouth, visual disturbance, and dizziness 1, 3, 5

Lifestyle Interventions

  • Regular physical exercise improves global IBS symptoms and should be recommended to all patients 2, 3
  • Creating dedicated time for relaxation and stress management is also recommended 1

Second-Line Treatment

  • The low-FODMAP diet is the most evidence-based dietary approach for IBS-D and should be implemented under dietitian supervision, with a three-phase approach: restriction, reintroduction, and personalization 2, 3, 5, 6
  • Trial probiotics for 12 weeks for global symptoms and abdominal pain, and discontinue if no improvement occurs after 12 weeks 2, 3, 5

Third-Line Treatment

  • Tricyclic antidepressants, such as amitriptyline, are the most effective treatment for global symptoms and abdominal pain in IBS-D, and should be started at 10 mg once daily at bedtime, titrating slowly to 30-50 mg daily 1, 3, 4, 5
  • Selective serotonin reuptake inhibitors, such as paroxetine, are equally effective alternatives to TCAs for global symptoms, but may accelerate small bowel transit, which may be less ideal for IBS-D 1, 3, 4
  • Augmentation strategy with a low-dose TCA can be added for persistent gastrointestinal symptoms when treating co-occurring depression with an SSRI 6

Fourth-Line Treatment

  • Cognitive behavioral therapy specific for IBS, delivered in 4-12 sessions, and gut-directed hypnotherapy, delivered in 7-12 sessions, are effective for global symptoms with strong recommendation 3, 5
  • Mindfulness-based stress reduction, targeting psychological stress and negative emotion, can also be considered 5

Critical Pitfalls to Avoid

  • Never start with insoluble fiber, such as wheat bran, as it will worsen symptoms, particularly bloating 2, 3
  • Do not promise complete symptom resolution, as the goal is symptom relief and improved quality of life 5
  • Avoid IgG antibody-based food elimination diets, as they lack evidence and may lead to unnecessary dietary restrictions 3
  • Do not recommend gluten-free diets unless celiac disease has been confirmed 3
  • Titrate loperamide carefully to avoid rebound constipation and abdominal pain 3
  • When prescribing TCAs, counsel patients extensively that these are gut-brain neuromodulators, not treatments for depression, to ensure adherence 3